Results 171 to 180 of about 137,963 (330)

Prevalence of Antimicrobial Use in Small Animal Dermatology Referral Practices in the United States

open access: yesVeterinary Dermatology, Volume 37, Issue 5, Page 581-591, October 2026.
ABSTRACT Background Antimicrobial resistance is a critical global health concern driven by antimicrobial use. Dermatological conditions are common reasons for antimicrobial prescriptions in small animal practice, yet data on prescribing patterns in veterinary dermatology referral settings are lacking. Hypothesis/Objectives To characterise the frequency,
Domenico Santoro   +2 more
wiley   +1 more source

‘Knowledge, attitudes and practices’ survey of Austrian veterinarians' antibiotic use in clinical practice

open access: yesVeterinary Record, Volume 199, Issue 5, Page e250-e261, 5/12 September 2026.
Abstract Background Antimicrobial resistance (AMR) is a critical global health issue, with antimicrobial use (AMU) in veterinary medicine playing a relevant role in its emergence. This study aimed to evaluate the knowledge, attitudes and practices of Austrian veterinarians regarding AMU and AMR.
Clair L. Firth   +4 more
wiley   +1 more source

Cephalosporin use and patient outcomes following removal of penicillin-cephalosporin cross-reactivity alerts from the electronic health record. [PDF]

open access: yesAntimicrob Agents Chemother
Zimmer A   +11 more
europepmc   +1 more source

Conformational Snapshots of CydDC in a Native Lipid Bilayer Coupling Heme Transport to Antibiotic Resistance

open access: yesAdvanced Science, Volume 13, Issue 50, 7 September 2026.
Phylogenetic and biochemical analyses of the heme transporter CydDC reveal its functional conservation throughout bacterial evolution and demonstrate its unique asymmetric allosteric mechanism. Furthermore, impairment of CydDC function directly affects bacterial antibiotic resistance and likely compromises antibiotic efficacy through drug efflux.
Lili Yang   +19 more
wiley   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan   +24 more
wiley   +1 more source

Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries. [PDF]

open access: yesClin Infect Dis
Hopkins J   +46 more
europepmc   +1 more source

Norwegian patients and retail chicken meat share cephalosporin-resistant Escherichia coli and IncK/blaCMY-2 resistance plasmids.

open access: yesClinical Microbiology and Infection, 2017
E. Berg   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy